Aprogen pharmaceuticals,Inc. (003060.KS)
KRW 704.0
(-4.22%)
KRW 704.0
(-4.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -49.29 Billion KRW | -424.03% |
| 2022 | 16 Billion KRW | 21.12% |
| 2021 | 11.38 Billion KRW | -20.93% |
| 2020 | 16.91 Billion KRW | 768.8% |
| 2019 | -2.8 Billion KRW | -123.02% |
| 2018 | 7.91 Billion KRW | 253.39% |
| 2017 | -5.83 Billion KRW | -1179.95% |
| 2016 | 1.47 Billion KRW | -82.47% |
| 2015 | 733.17 Million KRW | 218.57% |
| 2014 | -1.87 Billion KRW | 81.51% |
| 2013 | -18.93 Billion KRW | -2.72% |
| 2012 | -20.44 Billion KRW | -2704.09% |
| 2011 | -938.16 Million KRW | -43.87% |
| 2010 | 427.73 Million KRW | -66.0% |
| 2009 | -5.53 Billion KRW | 97.65% |
| 2008 | -6.39 Billion KRW | -50.37% |
| 2007 | -8.28 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -7.06 Billion KRW | 6.48% |
| 2024 Q1 | -7.55 Billion KRW | 78.68% |
| 2023 Q2 | -449.7 Million KRW | -112.77% |
| 2023 Q3 | -3.15 Billion KRW | -601.75% |
| 2023 Q4 | -35.42 Billion KRW | -1022.46% |
| 2023 FY | - KRW | -424.03% |
| 2023 Q1 | 3.52 Billion KRW | -5.13% |
| 2022 FY | - KRW | 21.12% |
| 2022 Q3 | -588.95 Million KRW | -259.03% |
| 2022 Q4 | 3.71 Billion KRW | 730.43% |
| 2022 Q2 | -164.03 Million KRW | -105.05% |
| 2022 Q1 | 3.25 Billion KRW | 1.77% |
| 2021 Q1 | 2.42 Billion KRW | 44.15% |
| 2021 Q2 | -234.56 Million KRW | -109.68% |
| 2021 Q3 | -31.74 Million KRW | 86.47% |
| 2021 FY | - KRW | -20.93% |
| 2021 Q4 | 3.19 Billion KRW | 10161.42% |
| 2020 Q2 | -151.27 Million KRW | -102.04% |
| 2020 FY | - KRW | 768.8% |
| 2020 Q4 | 1.68 Billion KRW | 2648.61% |
| 2020 Q3 | -65.97 Million KRW | 56.39% |
| 2020 Q1 | 7.41 Billion KRW | 438.48% |
| 2019 Q3 | -414.34 Million KRW | -351.15% |
| 2019 FY | - KRW | -123.02% |
| 2019 Q2 | 164.97 Million KRW | 103.18% |
| 2019 Q1 | -5.19 Billion KRW | -2797.46% |
| 2019 Q4 | 1.37 Billion KRW | 432.15% |
| 2018 Q3 | -134.54 Million KRW | -186.39% |
| 2018 FY | - KRW | 253.39% |
| 2018 Q1 | 673.93 Million KRW | -39.48% |
| 2018 Q2 | 155.73 Million KRW | -76.89% |
| 2018 Q4 | -179.25 Million KRW | -33.22% |
| 2017 Q2 | -285.91 Million KRW | -294.33% |
| 2017 Q3 | 219.1 Million KRW | 176.63% |
| 2017 FY | - KRW | -1179.95% |
| 2017 Q1 | 147.12 Million KRW | -48.75% |
| 2017 Q4 | 1.11 Billion KRW | 408.24% |
| 2016 FY | - KRW | -82.47% |
| 2016 Q1 | 133.42 Million KRW | -84.9% |
| 2016 Q4 | 287.08 Million KRW | 411.06% |
| 2016 Q3 | -92.29 Million KRW | -127.38% |
| 2016 Q2 | 337.07 Million KRW | 152.63% |
| 2015 Q2 | -10.35 Million KRW | -101.21% |
| 2015 Q3 | -100.34 Million KRW | -869.07% |
| 2015 FY | - KRW | 218.57% |
| 2015 Q4 | 883.7 Million KRW | 980.65% |
| 2015 Q1 | 854.73 Million KRW | 209.89% |
| 2014 Q2 | -573.98 Million KRW | 41.7% |
| 2014 Q3 | -702.83 Million KRW | -22.45% |
| 2014 FY | - KRW | 81.51% |
| 2014 Q1 | -984.56 Million KRW | 85.43% |
| 2014 Q4 | -777.82 Million KRW | -10.67% |
| 2013 Q4 | -6.75 Billion KRW | -433.71% |
| 2013 Q3 | -1.26 Billion KRW | 41.83% |
| 2013 FY | - KRW | -2.72% |
| 2013 Q1 | -5.48 Billion KRW | -3.83% |
| 2013 Q2 | -2.17 Billion KRW | 60.35% |
| 2012 Q4 | -5.28 Billion KRW | -186.03% |
| 2012 Q1 | -1.64 Billion KRW | 0.0% |
| 2012 Q2 | -8.16 Billion KRW | -395.31% |
| 2012 Q3 | -1.84 Billion KRW | 77.35% |
| 2012 FY | - KRW | -2704.09% |
| 2011 Q1 | 1.57 Billion KRW | 0.0% |
| 2011 Q2 | 872.06 Million KRW | -44.61% |
| 2011 Q3 | 201.65 Million KRW | -76.88% |
| 2011 FY | - KRW | -43.87% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | - KRW | -100.0% |
| 2010 Q1 | 1.3 Billion KRW | -10.07% |
| 2010 FY | - KRW | -66.0% |
| 2010 Q2 | 3.47 Billion KRW | 165.79% |
| 2009 FY | - KRW | 97.65% |
| 2009 Q3 | - KRW | -100.0% |
| 2009 Q1 | 1.74 Billion KRW | 594.07% |
| 2009 Q2 | 1.74 Billion KRW | 0.3% |
| 2009 Q4 | 1.45 Billion KRW | 0.0% |
| 2008 Q4 | -352.18 Million KRW | 0.0% |
| 2008 Q3 | - KRW | 100.0% |
| 2008 FY | - KRW | -50.37% |
| 2008 Q2 | -1.38 Billion KRW | 2.91% |
| 2008 Q1 | -1.42 Billion KRW | -1800.87% |
| 2007 Q3 | -6.34 Billion KRW | -12443.96% |
| 2007 Q2 | 51.42 Million KRW | 122.13% |
| 2007 Q1 | -232.35 Million KRW | 0.0% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q4 | -75.13 Million KRW | 98.82% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 1114.584% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 134.869% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 23.025% |
| HANDOK Inc. | 35.06 Billion KRW | 240.566% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | -4655.265% |
| Yuhan Corporation | 127.43 Billion KRW | 138.681% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 231.371% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | -127.282% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 115.245% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | 1087.749% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 426.042% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | 1540.873% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | 1188.986% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 238.904% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 1114.584% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | -166.849% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | 851.978% |
| JW Holdings Corporation | 187.88 Billion KRW | 126.235% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 3.78% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 117.379% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 155.247% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | -32.981% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 473.152% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | 516.744% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 364.231% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 1114.584% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 189.666% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 129.89% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 155.247% |
| Yuhan Corporation | 127.43 Billion KRW | 138.681% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 247.246% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | 744.353% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 163.992% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 155.247% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 234.551% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 169.641% |
| CKD Bio Corp. | -1.63 Billion KRW | -2923.22% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 198.994% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 251.381% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 233.908% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | -32.981% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 179.14% |
| Boryung Corporation | 114.28 Billion KRW | 143.13% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | -61.252% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 426.042% |
| JW Lifescience Corporation | 50.82 Billion KRW | 196.976% |